About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Dr. Goldenberg presents recent studies on various cancers and the implications of new and existing therapies.
Marvin M. Goldenberg, PhD
Drug Shortages (4-Part Series)
The results of the ISMP’s recent national survey on drug shortages are discussed, along with guidelines on how to handle drug shortages.
Matthew Grissinger, RPh
Pharmaceutical Spotlight: Recombinant Human Activated Protein C (rhAPC) or Drotrecogin Alfa (Activated)
This article focuses on the revolutionary new drug
that combats a highly complicated disease: sepsis.
Michelle Leady, PharmD, Michael Kraft PharmD, and Cesar Alaniz, PharmD
Despite the widely held belief that therapy with PPIs renders patients asymptomatic, breakthrough symptoms are common.
Malcom Robinson, MD and Kimberly Shaw, BA
Measuring Patients’ Health-Related Quality of Life: Practical Considerations for Implementing an Outcomes Management Program
Patient self-administered questionnaires could help determine health-related quality of life in outcomes management.
Jennifer Lofland, PharmD
Is a placebo-controlled trial ethical if an effective treatment has already been established? The author discusses the issue with Robert Temple, MD.
Editor-in-Chief David B. Nash discusses what is
needed for an effective “Sepsis Segue.”
David Nash, MD, MBA